Summit Therapeutics (SMMT) Free Cash Flow (2020 - 2026)

Summit Therapeutics has reported Free Cash Flow for 7 years, with the latest figure at -$123.0 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 99.77% year-over-year to -$123.0 million; the trailing twelve-month figure through Mar 2026 stood at -$385.0 million (down 121.67% YoY), and the FY2025 full-year result was -$323.6 million, down 127.49% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$123.0 million, down from -$102.1 million in the prior quarter.
• The five-year high for Free Cash Flow was $5.2 million in Q4 2022, with the low at -$123.0 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$41.6 million across 5 years, with a median of -$30.1 million in 2024.
• Annual changes were most pronounced in 2022 — Free Cash Flow jumped 155.93% — and 2023, when it slumped 474.18%.
• Summit Therapeutics' Free Cash Flow stood at $5.2 million in 2022, then tumbled by 474.18% to -$19.5 million in 2023, then plunged by 150.82% to -$48.8 million in 2024, then tumbled by 109.17% to -$102.1 million in 2025, then dropped by 20.5% to -$123.0 million in 2026.
• The last three Free Cash Flow figures came in at -$123.0 million (Q1 2026), -$102.1 million (Q4 2025), and -$93.5 million (Q3 2025), per Business Quant data.